Keyphrases
Activating Receptors
7%
ALT-803
18%
Antibody-dependent Cellular Cytotoxicity
20%
Anticancer Activity
5%
Antigen Specificity
7%
Ascites
7%
Bike
8%
Bispecific
28%
Cancer Stem Cells
8%
CD133
18%
CD16
20%
CD33
49%
Chromium Release Assay
5%
Continuous Treatment
18%
Cross-linker
7%
Cytokine Release
5%
Cytolytic Activity
18%
Degranulation
8%
Drug Refractory
5%
Engager
64%
Enhanced Functions
18%
Expansion Function
18%
Flow Cytometry
5%
HL-60 Cells
5%
Human NK Cells
20%
Inflammatory Response
6%
Interferon-α (IFN-α)
8%
Interleukin-15 (IL-15)
89%
Lysis
6%
Metabolic Defects
18%
Myelodysplastic Syndrome
17%
Myeloid-derived Suppressor Cells
18%
Natural Killer
23%
Natural Killer Cell Activity
29%
Natural Killer Cell Expansion
7%
Natural Killer Cells
100%
NK Cell Activity
5%
Ovarian Cancer
18%
Ovarian Cancer Patients
9%
Primary Myelodysplastic Syndrome
18%
Relapsed or Refractory
5%
ScFv
13%
Superagonist
18%
TriKE
25%
Trispecific
56%
Tumor Control
5%
Immunology and Microbiology
Antibody-Dependent Cell-Mediated Cytotoxicity
21%
Antigen Specificity
7%
Antineoplastic Activity
8%
Cancer Stem Cell
9%
CD16
18%
CD33
41%
Cell Expansion
5%
Cell Function
8%
Cytokine Release
6%
Degranulation
12%
Interferon Type I
9%
Interleukin 15
34%
Killer Cell
18%
Myeloid
6%
Myeloid-Derived Suppressor Cell
18%
Natural Killer Cell
94%
Medicine and Dentistry
Antibody Dependent Cellular Cytotoxicity
18%
Antineoplastic Activity
8%
Ascites
5%
Cancer Stem Cell
9%
Cell Function
20%
Cytokine Release
6%
Cytotoxicity
5%
Degranulation
8%
Interferon
9%
Interleukin 15
34%
Natural Killer Cell
56%
Ovarian Cancer
18%